康弘药业：全资子公司获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for the drug KH816 injection [1] Group 2 - Kanghong Pharmaceutical announced the approval on January 14, indicating progress in their drug development pipeline [1] - The article also highlights a separate case involving Haili Biotechnology, which has seen a significant valuation drop despite a previous ninefold increase due to unusual circumstances surrounding its largest client [1]